𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

✍ Scribed by Bengt Winblad; Niels Andreasen; Lennart Minthon; Annette Floesser; Georges Imbert; Thomas Dumortier; R Paul Maguire; Kaj Blennow; Joens Lundmark; Matthias Staufenbiel; Jean-Marc Orgogozo; Ana Graf

Book ID
117792162
Publisher
The Lancet
Year
2012
Tongue
English
Weight
606 KB
Volume
11
Category
Article
ISSN
1474-4465

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A 24-week, double-blind, placebo-control
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease—pilot study
✍ Vee. P. Prasher; Adam Huxley; M. S. Haque 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

## Abstract ## Background Donepezil Hydrochloride (Aricept) is a selective anticholinesterase inhibitor developed for the treatment of Alzheimer's disease (AD). This study investigated the safety and efficacy of the drug to treat Down syndrome (DS) adults with mild to moderate AD. ## Method This

A multicentre, randomized, double-blind,
A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study
✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre